WINDTREE THERAPEUTICS INC (WINT)       0.38  +0 (+0.26%)

0.38  +0 (+0.26%)

US97382D3035 - Common Stock - After market: 0.38 0 (0%)


Fundamental Rating

Taking everything into account, WINT scores 2 out of 10 in our fundamental rating. WINT was compared to 644 industry peers in the Biotechnology industry. WINT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, WINT is valued expensive at the moment.




Profitability

Profitability Rating


WINT has negative profitability rations, so we won't be analyzing them here.
WINT has a Return On Assets of -99.54%. This is below the industry average of -40.28%. 86% of the industry peers outperform WINT.

The Piotroski-F score of WINT is 2.00. This is a very weak score and indicates problems in health and profitability for WINT.
VS Industry

ROA (-99.54%) VS Industry: 14% outperformed.

-1,226.49
115.38

Valuation

Valuation Rating


With a price book ratio of 0.32, WINT is valued rather cheaply.
When comparing the price book ratio of WINT to the average industry price book ratio of 1.93, WINT is valued rather cheaply. WINT is also cheaper than 98% of the companies listed in the same industry.

WINT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WINT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.32) VS Industry: 98% outperformed.

669.86
0.07

Growth

Growth Rating


WINT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.54%, which is quite impressive.

WINT is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 11.97% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 47.54% 57.44% 26.69% 23.19% 11.97%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating


WINT has a Current Ratio of 3.46. This indicates that WINT is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.46 indicates that WINT has no problem at all paying its short term obligations.
When comparing the Current Ratio of WINT to the average industry Current Ratio of 6.72, WINT is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.60, WINT is worse placed to pay its short term obligations than its industry peers.

WINT has one of the worst Debt to Equity ratios in its industry. 88% of its industry peers require less debt for financing their operations.
WINT has an Altman-Z score of -19.90. This is a bad value and indicates that WINT is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of WINT to the average industry Altman-Z score of 0.63, WINT is less financially healthy than its industry peers. 95% of its industry peers have a better Altman-Z score.
The Piotroski-F score of WINT is 2.00. This is a very weak score and indicates problems in health and profitability for WINT.
VS Industry

Debt/Equity (0.43) VS Industry: 12% outperformed.

18.24
0.00

Quick Ratio (3.46) VS Industry: 26% outperformed.

0.04
138.86

Current Ratio (3.46) VS Industry: 26% outperformed.

0.15
140.77

Altman-Z (-19.9) VS Industry: 5% outperformed.

-253.58
1,332.86

Dividend

Dividend Rating


No dividends for WINT!.

WINT Daily chart

WINDTREE THERAPEUTICS INC0.38

NASDAQ:WINT (8/16/2022, 7:06:36 PM)+0 (+0.26%)

After market: 0.38 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-03 2022-08-03 Earnings (Next) 11-08 2022-11-08
Ins Owners N/A Inst Owners 5.08%
Market Cap 11.17M Analysts 87.5
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.32
EV/EBITDA -0.36
Profitability
ROA -99.54% ROE N/A
PM N/A Asset Turnover N/A
Growth
EPS 1Y 47.54% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 43.73%
EPS Next Y 57.44% EPS Next 2Y 26.69%
EPS Next 3Y 23.19% EPS Next 5Y 11.97%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 3.46 Quick Ratio 3.46
Altman-Z -19.9 F-Score 2
Debt/Equity 0.43
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA